New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation with bexicaserin in patients with Developmental and Epileptic Encephalopathies (DEEs)1 DEEs are a group […]
Tag: H. Lundbeck A/S
Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting USA – English USA – English
New long-term data presented at AES 2025 indicate reductions in seizure frequency are maintained for up to two years after treatment initiation with bexicaserin in patients with Developmental and Epileptic Encephalopathies (DEEs)1 DEEs are a group […]
Lundbeck files for marketing authorization across key Asian markets for Vyepti® (eptinezumab) for the preventive treatment of migraine
Lundbeck’s new drug application (NDA) for Vyepti® (eptinezumab) accepted by Japan’s Ministry of Health, Labor and Welfare (MHLW), marking a significant step forward towards expanding access to the novel preventive migraine treatment for patients across Japan […]
